Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823793 | 0.95 | HDAC1 (0.41) | NAMPTHDAC1DDB1CRBNESR2 | |
| SCHEMBL28037308 | 0.87 | NAMPT (0.37) | NAMPTHDAC1DDB1CRBNESR2 | |
| SCHEMBL17380554 | 0.86 | DDB1 (0.36) | NAMPTHDAC1DDB1CRBNESR2 | |
| SCHEMBL18788487 | 0.86 | DDB1 (0.36) | NAMPTHDAC1DDB1CRBNESR2 | |
| SCHEMBL14358443 | 0.84 | HDAC1 (0.40) | NAMPTHDAC1DDB1CRBNESR2 | |
| SCHEMBL17380568 | 0.82 | HDAC1 (0.39) | NAMPTHDAC1DDB1CRBNESR2 | |
| SCHEMBL2364142 | 0.81 | DPP4 (0.41) | NAMPTDPP4DPP8DPP7SLC6A9 | |
| SCHEMBL21257533 | 0.78 | USP9X (0.46) | NAMPTHDAC1ESR2DPP4NR1H2 | |
| SCHEMBL24507073 | 0.77 | SLC34A1 (0.43) | NAMPTHDAC1DDB1CRBNESR2 | |
| SCHEMBL19203380 | 0.76 | USP2 (0.45) | NAMPTHDAC1ESR2MAPTNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3159344-B1 | AMINO PYRANOID RING DERIVATIVE AND COMPOSITION AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) | 2023-09-20 | — | — | EP | disclosed |
| US-20170121338-A1 | AMINO PRYAN RING DERIVATIVE AND COMPOSITION AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD (CN) | 2017-05-04 | — | — | US | disclosed |
| US-20170121338-A1 | AMINO PRYAN RING DERIVATIVE AND COMPOSITION AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD (CN) | 2017-05-04 | — | — | US | disclosed |
| US-20170121338-A1 | AMINO PRYAN RING DERIVATIVE AND COMPOSITION AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD (CN) | 2017-05-04 | — | — | US | disclosed |
| EP-3159344-A1 | AMINO PYRANOID RING DERIVATIVE AND COMPOSITION AND USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2017-04-26 | — | — | EP | disclosed |
| EP-3159344-A1 | AMINO PYRANOID RING DERIVATIVE AND COMPOSITION AND USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2017-04-26 | — | — | EP | disclosed |
| EP-2676961-B1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2676960-B1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9403790-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160137622-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2016-05-19 | — | — | US | disclosed |
| EP-2676959-A1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | Merck Sharp & Dohme Corporation (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2676960-A1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | Merck Sharp & Dohme Corp. (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2676961-A1 | Combination drugs comprising aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | Merck Sharp & Dohme Corporation (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8592371-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARPE & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2358717-B1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20130157940-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME CORP (US) | 2013-06-20 | — | — | US | disclosed |
| US-8415297-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120149637-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
| US-8143289-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | NAMPT 801/4885HDAC1 2431/4885DDB1 2076/4885 |
| US-20170121338-A1 | AMINO PRYAN RING DERIVATIVE AND COMPOSITION AND USE THEREOF | DPP4, DPP8, DPP3 | NAMPT 1539/4885HDAC1 636/4885DDB1 2091/4885 |
| US-20130157940-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | NAMPT 801/4885HDAC1 2431/4885DDB1 2076/4885 |
| US-20120149637-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | NAMPT 801/4885HDAC1 2431/4885DDB1 2076/4885 |
| US-20160137622-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | NAMPT 801/4885HDAC1 2431/4885DDB1 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.